參考文獻/References:
[1] 中華醫(yī)學(xué)會骨科學(xué)分會關(guān)節(jié)外科學(xué)組,中國醫(yī)師協(xié)會骨科醫(yī)師分會骨關(guān)節(jié)炎學(xué)組,國家老年疾病臨床醫(yī)學(xué)研究中心(湘雅醫(yī)院),等.中國骨關(guān)節(jié)炎診療指南(2021年版)[J].中華骨科雜志,2021,41(18):1291-1314.
[2] 馮媛媛,羅亞萍,師靜,等.膝骨關(guān)節(jié)炎患者關(guān)節(jié)疼痛與軟骨下骨髓水腫的相關(guān)性研究[J].現(xiàn)代生物醫(yī)學(xué)進展,2018,18(6):1155-1158.
[3] 常亮,秦江輝,史冬泉,等.骨關(guān)節(jié)炎與軟骨下骨研究進展[J].中華骨與關(guān)節(jié)外科雜志,2019,12(10):827-832.
[4] JAIPRAKASH A,PRASADAM I,FENG J Q,et al.Phenotypic characterization of osteoarthritic osteocytes from the sclerotic zones:a possible pathological role in subchondral bone sclerosis[J].Int J Biol Sci,2012,8(3):406-417.
[5] VILLATORO-VILLAR M,KWOH C K.Bisphosphonates,bone and joint pain[J].Curr Osteoporos Rep,2021,19(4):417-428.
[6] PANAGIOTAKOU A,YAVROPOULOU M,NASIRI-ANSARI N,et al.Extra-skeletal effects of bisphosphonates[J/OL].Metabolism,2020,110:154264[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/32445641/.
[7] 楊威,魯艷芹,韓金祥.雙膦酸鹽類藥物及其應(yīng)用綜述[J].罕少疾病雜志,2021,28(6):105-110.
[8] ITZSTEIN C,COXON F P,ROGERS M J.The regulation of osteoclast function and bone resorption by small GTPases[J].Small GTPases,2011,2(3):117-130.
[9] HOLSTEIN S A.A patent review of bisphosphonates in treating bone disease[J].Expert Opin Ther Pat,2019,29(5):315-325.
[10] PARK J,PANDYA V R,EZEKIEL S J,et al.Phosphonate and bisphosphonate inhibitors of farnesyl pyrophosphate synthases:a structure-guided perspective[J/OL].Front Chem,2021,8:612728[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/33490038/.
[11] MATHOV I,PLOTKIN L I,SGARLATA C L,et al.Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro[J].J Bone Miner Res,2001,16(11):2050-2056.
[12] BABA T T,MIYAZAKI T,OHARA-NEMOTO Y,et al.Suppressive effects of N-bisphosphonate in osteoblastic cells mitigated by non-N-bisphosphonate but not by sodium-dependent phosphate cotransporter inhibitor[J].Cell Biochem Funct,2019,37(6):400-407.
[13] PLOTKIN L I,BUVINIC S,BALANTA-MELO J.In vitro and in vivo studies using non-traditional bisphosphonates[J/OL].Bone,2020,134:115301[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/32112989/.
[14] LOTZ E M,LOHMANN C H,BOYAN B D,et al.Bisphosphonates inhibit surface-mediated osteogenesis[J].J Biomed Mater Res A,2020,108(8):1774-1786.
[15] ROELOFS A J,THOMPSON K,EBETINO F H,et al.Bisphosphonates:molecular mechanisms of action and effects on bone cells,monocytes and macrophages[J].Curr Pharm Des,2010,16(27):2950-2960.
[16] WANG L,MI B,ZHANG Y,et al.Alendronate promotes the gene expression of extracellular matrix mediated by SP-1/SOX-9[J].Hum Exp Toxicol,2021,40(7):1173-1182.
[17] 韓蕓,韓偉,盧瓊.阿侖膦酸鈉對膝骨關(guān)節(jié)炎大鼠軟骨細胞的保護作用[J].中國臨床藥理學(xué)雜志,2020,36(20):3321-3323.
[18] ROSA R G,COLLAVINO K,LAKHANI A,et al.Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway[J].Osteoarthritis Cartilage,2014,22(9):1327-1336.
[19] JIN Z H,WANG S F,LIAO W.Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis[J].Eur Rev Med Pharmacol Sci,2020,24(4):2095-2101.
[20] DELANOIS R E,SAX O C,CHEN Z,et al.Biologic therapies for the treatment of knee osteoarthritis:an updated systematic review[J].J Arthroplasty,2022,37(12):2480-2506.
[21] VALENTI M T,MOTTES M,BIOTTI A,et al.Clodronate as a therapeutic strategy against osteoarthritis[J].Int J Mol Sci,2017,18(12):2696.
[22] 楊爽,閆景龍.軟骨細胞分化過程中SOX9的作用[J].中國組織工程研究,2022,26(14):2279-2284.
[23] TAKIGAWA Y,HATA K,MURAMATSU S,et al.The transcription factor Znf219 regulates chondrocyte differentiation by assembling a transcription factory with Sox9[J].J Cell Sci,2010,123(Pt 21):3780-3788.
[24] WOOD M J,MILLER R E,MALFAIT A M.The genesis of pain in osteoarthritis:inflammation as a mediator of osteoarthritis pain[J].Clin Geriatr Med,2022,38(2):221-238.
[25] WOODELL-MAY J E,SOMMERFELD S D.Role of inflammation and the immune system in the progression of osteoarthritis[J].J Orthop Res,2020,38(2):253-257.
[26] PAN F,TIAN J,CICUTTINI F,et al.Prospective association between inflammatory markers and knee cartilage volume loss and pain trajectory[J].Pain Ther,2022,11(1):107-119.
[27] WANG X Z,LI W X.Changes of serum inflammatory factors and miR-145 expression in patients with osteoarthritis before and after treatment and their clinical value[J].World J Clin Cases,2019,7(19):2963-2975.
[28] 王哲彥,王文雅,張柳,等.阿侖膦酸鈉對IL-1β體外誘導(dǎo)培養(yǎng)的大鼠膝關(guān)節(jié)軟骨細胞影響的實驗研究[J].中國修復(fù)重建外科雜志,2011,25(1):50-55.
[29] PERIS P,MONEGAL A,GUAÑABENS N.Bisphosphonates in inflammatory rheumatic diseases[J/OL].Bone,2021,146:115887[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/33592328/.
[30] BAROJA-MAZO A,PELEGRÍN P.Modulating P2X7 receptor signaling during rheumatoid arthritis:new therapeutic approaches for bisphosphonates[J/OL].J Osteoporos,2012,2012:408242[2022-10-10].https://pubmed.ncbi.nlm.nih.gov/22830074/.
[31] ZHANG H,CAI D,BAI X.Macrophages regulate the progression of osteoarthritis[J].Osteoarthritis Cartilage,2020,28(5):555-561.
[32] XIE J,HUANG Z,YU X,et al.Clinical implications of macrophage dysfunction in the development of osteoarthritis of the knee[J].Cytokine Growth Factor Rev,2019,46:36-44.
[33] PATNTIRAPONG S,POOLGESORN M.Alteration of macrophage viability,differentiation,and function by bisphosphonates[J].Oral dis,2018,24(7):1294-1302.
[34] PATNTIRAPONG S,PHUPUNPORN P,VANICHTANTIPHONG D,et al.Inhibition of macrophage viability by bound and free bisphosphonates[J].Acta Histochem,2019,121(4):400-406.
[35] MAKKONEN N,SALMINEN A,ROGERS M J,et al.Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite[J].Eur J Pharm Sci,1999,8(2):109-118.
[36] VILLATORO-VILLAR M,KWOH C K.Bisphosphonates,bone and joint pain[J].Curr Osteoporos Rep,2021,19(4):417-428.
[37] TAYLOR S S,NOOR N,URITS I,et al.Complex regional pain syndrome:a comprehensive review[J].Pain Ther,2021,10(2):875-892.
[38] FREDIANI B,GIUSTI A,BIANCHI G,et al.Clodronate in the management of different musculoskeletal conditions[J].Minerva Med,2018,109(4):300-325.
[39] FREDIANI B,TOSCANO C,FALSETTI P,et al.Intramuscular clodronate in long-term treatment of symptomatic knee osteoarthritis:a randomized controlled study[J].Drugs R D,2020,20(1):39-45.
[40] TZSCHENTKE T M.Pharmacology of bisphosphonates in pain[J].Br J Pharmacol,2021,178(9):1973-1994.
[41] HAYAMI T,PICKARSKI M,WESOLOWSKI G A,et al.The role of subchondral bone remodeling in osteoarthritis:reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model[J].Arthritis Rheum,2004,50(4):1193-1206.
[42] STRASSLE B W,MARK L,LEVENTHAL L,et al.Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease[J].Osteoarthritis Cartilage,2010,18(10):1319-1328.
[43] 陳建超.抗骨質(zhì)疏松聯(lián)合用藥對骨質(zhì)疏松癥伴膝骨關(guān)節(jié)炎患者骨量分布的影響[D].唐山:華北理工大學(xué),2021.
[44] NEOGI T,LI S,PELOQUIN C,et al.Effect of bisphosphonates on knee replacement surgery[J].Ann Rheum Dis,2018,77(1):92-97.
[45] VERTESICH K,SOSA B R,NIU Y,et al.Alendronate enhances osseointegration in a murine implant model[J].J Orthop Res,2021,39(4):719-726.
[46] WANG P,SHANG G Q,XIANG S,et al.Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model[J].BMC Musculoskelet Disord,2021,22(1):580.
[47] RO D H,JIN H,PARK J Y,et al.The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate[J].Knee Surg Sports Traumatol Arthrosc,2019,27(7):2082-2089.
[48] PRIETO-ALHAMBRA D,LALMOHAMED A,ABRAHAMSEN B,et al.Oral bisphosphonate use and total knee/hip implant survival:validation of results in an external population-based cohort[J].Arthritis Rheumatol,2014,66(11):3233-3240.
[49] NAMBA R S,INACIO M C S,CHEETHAM T C,et al.Lower total knee arthroplasty revision risk associated with bisphosphonate use,even in patients with normal bone density[J].J Arthroplasty,2016,31(2):537-541.
[50] SHI M,CHEN L,XIN Z,et al.Bisphosphonates for the pre-servation of periprosthetic bone mineral density after total joint arthroplasty:a meta-analysis of 25 randomized controlled trials[J].Osteoporos Int,2018,29(7):1525-1537.
[51] LEMS W F.Bisphosphonates:a therapeutic option for knee osteoarthritis?[J].Ann Rheum Dis,2018,77(9):1247-1248.
[52] YUAN X L,MENG H Y,WANG Y C,et al.Bone-cartilage interface crosstalk in osteoarthritis:potential pathways and future therapeutic strategies[J].Osteoarthritis Cartilage,2014,22(8):1077-1089.
[53] LASLETT L L,DORÉ D A,QUINN S J,et al.Zoledronic acid reduces knee pain and bone marrow lesions over 1 year:a randomised controlled trial[J].Ann Rheum Dis,2012,71(8):1322-1328.
[54] AGARWALA S,SHAROFF L,JAGANI N.Effect of zoledronic acid and alendronate on bone edema and pain in spontaneous osteonecrosis of the knee:a new paradigm in the medical management[J].Rev Bras Ortop(Sao Paulo),2020,55(5):543-550.
[55] HAYES K N,GIANNAKEAS V,WONG A K O.Bisphosphonate use is protective of radiographic knee osteoarthritis progression among those with low disease severity and being non-overweight:data from the osteoarthritis initiative[J].J Bone Miner Res,2020,35(12):2318-2326.
(收稿日期:2022-10-11 本文編輯:郭毅曼)